The Wellcome Trust, an independent global charitable foundation dedicated to improving health through science, research and engagement with society, has announced that Kevin Moses, Director of Science, will be leaving the Trust in August later this year. He is returning to the United States to become a partner of The Column Group, a venture capital firm building on novel scientific ideas from the academic sector and early stage companies. His new role will take him closer to family based in the US.
Since joining Wellcome in 2011, from the Howard Hughes Janelia Farm Research Campus in Virginia where he was Chief Academic Officer, Kevin has led a significant period of evolution for Wellcome's science funding portfolio and managed many other significant and strategic changes within the Science Division and more broadly across the organisation as a member of the Executive Board.
Kevin will continue to lead the Science Division between now and August while the search for a replacement is undertaken.
In a related announcement, it has been announced that Pharmaceutical industry expert William (Bill) Burns will join the Board of Governors of the Wellcome Trust this week.
Bill Burns has spent his entire career in the life sciences industry. He was CEO of the global Pharmaceutical Division of Roche from 2001-2009, before joining the main Roche board until 2014. Today he is a non-executive director of Shire Pharmaceuticals and Mesoblast, Vice Chairman of Vestergaard and Chairman of Biotie Therapies. In addition he serves as a trustee to the Institute of Cancer Research.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
